Is there a history of AIP in your family?
Who provides you with support in managing your disorder?
During an AIP attack, what symptom(s) do you experience the most often?
What kinds of things do you do to stay positive?
You are about to leave the PANHEMATIN (hemin for injection) website and enter a website operated by an independent third party. The links to third-party websites contained on AIPorphyria.com are provided solely for your convenience. Lundbeck does not control the opinions, claims or comments contained on any third-party website linked to AIPorphyria.com, and your activities at those websites will be governed by the policies and practices of those third parties.
Take a survey and tell us your
ideas for spreading AIP awareness.
Survey results are displayed
immediately, so you can see other
people’s thoughts, too.
Download a family discussion guide
and make sure your family has the
AIP information they need.
Our new infographic, "The Little Imitator", is a great tool for helping other people understand AIP. Get your copy and start sharing!
Help others with AIP learn about life with the disorder. Tell the community about your experiences.
The toolkit for healthcare
professionals provides essential
information on AIP and the use of
Panhematin.
Your clinical experiences are valuable to other healthcare professionals. Share your knowledge in an AIP case study.
Dr. Karl Anderson discusses the pathophysiology of the disorder and explains a key diagnostic test.
Watch the video
View a tutorial that explains how to prepare and administer Panhematin.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/MedWatch, or call 1-800-FDA-1088.
PANHEMATIN (hemin for injection) is a prescription medication used to relieve repeated attacks of acute intermittent porphyria related to the menstrual cycle in affected women.
Signs and symptoms of acute intermittent porphyria such as pain, high blood pressure, rapid heart beat, abnormal mental status and mild to progressive neurologic signs (including seizures and paralysis) may be controlled in some patients with this disorder.
Similar findings have been reported in other patients with acute intermittent porphyria, porphyria variegata and hereditary coproporphyria. PANHEMATIN is not indicated in porphyria cutanea tarda.
PANHEMATIN does not cure acute intermittent porphyria. After stopping PANHEMATIN treatment, symptoms usually return, although some patients experience a period without symptoms.
PANHEMATIN should only be used by doctors experienced in the management of porphyrias in hospitals where the recommended clinical and laboratory diagnostic and monitoring practices are available.
PANHEMATIN therapy should be considered after an appropriate period of alternate therapy (i.e., 400 g glucose/day for 1 to 2 days).
PANHEMATIN is not for patients known to be allergic to this drug. PANHEMATIN is made from human blood and therefore may contain agents that can cause infections, such as viruses, that can cause disease including Creutzfeldt-Jakob disease.
Drugs such as estrogens, barbituric acid derivatives, steroid-like drugs, and blood thinners should be avoided during PANHEMATIN therapy. Your doctor should monitor your iron levels if you receive multiple courses of PANHEMATIN.
Reversible kidney shutdown has occurred with high doses. Because vein inflammation has been reported after administering PANHEMATIN through small arm veins, a large arm vein or a central line should be used.
For more information, please see Full Prescribing Information including Boxed Warning at www.lundbeckus.com.
PHT117R1
Panhematin is a registered trademark of Lundbeck.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/MedWatch, or call 1-800-FDA-1088.
PANHEMATIN (hemin for injection) is indicated for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women.
Manifestations such as pain, hypertension, tachycardia, abnormal mental status and mild to progressive neurologic signs may be controlled in selected patients with this disorder.
Similar findings have been reported in other patients with acute intermittent porphyria, porphyria variegata and hereditary coproporphyria. PANHEMATIN is not indicated in porphyria cutanea tarda.
PANHEMATIN should only be used by physicians experienced in the management of porphyrias in hospitals where the recommended clinical and laboratory diagnostic and monitoring techniques are available.
PANHEMATIN therapy should be considered after an appropriate period of alternate therapy (i.e., 400 g glucose/day for 1 to 2 days).
PANHEMATIN is contraindicated in patients with known hypersensitivity to this drug. PANHEMATIN is made from human blood and therefore may contain infectious agents, such as viruses, that can cause disease including Creutzfeldt-Jakob disease.
Drugs such as estrogens, barbituric acid derivatives, steroid metabolites, and anticoagulants should be avoided during PANHEMATIN therapy. Increased levels of iron and serum ferritin have been reported in post-marketing experience; therefore, physicians should monitor iron and serum ferritin in patients receiving multiple administrations of PANHEMATIN.
Reversible renal shutdown has occurred with administration of excessive doses. Because phlebitis has been reported after administration of PANHEMATIN through small arm veins, a large arm vein or a central venous catheter should be utilized for administration.
For more information, please see Full Prescribing Information including Boxed Warning at www.lundbeckus.com.
PHT116R1
This site contains medical information that is intended for residents of the United States only and is not meant to substitute for the advice provided by a medical professional. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Privacy Policy and Terms of Use.
The characters depicted are actors and not healthcare professionals or actual patients.
© 2013 Lundbeck Deerfield, IL 60015. All rights reserved. PHT110R11